sellWeak cluster of 410b5-1 plan
Charles McWherter sold $436k of CBAY
President of R&D at CymaBay Therapeutics, Inc.. 18,403 shares at an average of $23.67, traded Jan 19, 2024, filed Jan 22, 2024.
Warning score
37Value
$436k
18,403 shares
Holdings after
15,000
-107% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- +17Trade size$436k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-24-001164, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 19, 2024 | MOption exercise Common Stock10b5-1 | +2,250 | $1.06 | $2,385 | 17,250 | Jan 22, 2024 |
| Jan 19, 2024 | SOpen-market sale Common Stock10b5-1 | -2,250 | $23.67 | $53k | 15,000 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Common Stock10b5-1 | +2,778 | $1.72 | $4,778 | 17,778 | Jan 22, 2024 |
| Jan 19, 2024 | SOpen-market sale Common Stock10b5-1 | -2,778 | $23.66 | $66k | 15,000 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Common Stock10b5-1 | +1,916 | $1.82 | $3,487 | 16,916 | Jan 22, 2024 |
| Jan 19, 2024 | SOpen-market sale Common Stock10b5-1 | -1,916 | $23.66 | $45k | 15,000 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Common Stock10b5-1 | +8,334 | $10.00 | $83k | 23,334 | Jan 22, 2024 |
| Jan 19, 2024 | SOpen-market sale Common Stock10b5-1 | -8,334 | $23.68 | $197k | 15,000 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Common Stock10b5-1 | +3,125 | $11.69 | $37k | 18,125 | Jan 22, 2024 |
| Jan 19, 2024 | SOpen-market sale Common Stock10b5-1 | -3,125 | $23.68 | $74k | 15,000 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,250 | $0.00 | $0 | 51,750 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,778 | $0.00 | $0 | 97,222 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,916 | $0.00 | $0 | 44,084 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -8,334 | $0.00 | $0 | 91,666 | Jan 22, 2024 |
| Jan 19, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -3,125 | $0.00 | $0 | 146,875 | Jan 22, 2024 |
Related signals
Other insiders at CymaBay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $192k 6,000 shares | -100% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $118k 5,000 shares | -100% | |
| 28Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $236k 10,000 shares | -100% | |
| 26Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $143k 6,000 shares | -100% | |
| 33Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $243k 11,332 shares | -57% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $110k 5,000 shares | -100% | |
| 32Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $473k 21,497 shares | -215% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $120k 6,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.3M 64,865 shares | -28% | |
| 24Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $87k 5,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.